drugset / Trial / NCT02143531

Intravenous Haloperidol Versus Ondansetron for Treatment of Established Post-operative Nausea and Vomiting

NCT02143531

Phase 4 Completed 120 enrolled American University of Beirut Medical Center
RandomizedParallel-groupDouble-blindTreatment

Summary

This study aims to prove that at a dose of 1 mg Haloperidol possesses a high success rate in controlling established postoperative nausea and vomiting (PONV) in the first 24 hours following administration similar to the standard of care ondansetron 4 mg.

Timeline

Start
2008-09
Primary completion
2012-08
Completion
2012-08

Drugs

EvaluationDrugModalityDoseRoute
Comparator Haloperidol Other / unclassified 1 mg Intravenous
Comparator Ondansetron Other / unclassified 4 mg Intravenous

Indications

No indication recorded.